S1节拍化疗联合多西他赛治疗晚期非小细胞肺癌的临床观察

Clinical Observation of S1 Metronomic Chemotherapy Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer

目的:回顾性的讨论分析我中心S1节拍化疗联合多西他赛治疗晚期一线治疗失败的非小细胞肺癌病例。方法:收集2016年1月—2018年12月我院收治的48例接受口服S1节拍化疗联合多西他赛治疗晚期一线治疗失败的NSCLC的临床资料,进行回顾性分析。结果:中位随访时间为14(5~29)个月。患者的中位治疗周期数为2(1~8)个,无患者达到完全缓解,6例(12.5%)患者达部分缓解,20例(41.7%)达疾病稳定,22例(45.8%)为疾病进展。患者的有效率为12.5%,疾病控制率为54.2%。中位疾病无进展时间(Progression-free survival,PFS)为4个月。治疗的耐受性一般,有严重毒性反应发生。结论:口服S1节拍化疗联合多西他赛可作为治疗晚期NSCLC选择性人群的治疗方案,但需要进一步探讨其最佳的使用剂量和联合方式。

Objective:Retrospectively discussed and analyzed the cases of non-small cell lung cancer that failed first-line treatment in S1 metronomic chemotherapy combined with docetaxel in our center.Methods:Our retrospective study enrolled 48 patients who received metronomic oral S1 with conventional chemotherapy Survival factors were evaluated.Results:The median follow-up was 14(5~29)months.The median number of treatment cycles was 2(1~8),no patients achieved complete remission,6(12.5%)partial remission,20(41.7%)stable disease,and 22(45.8%)progression disease.Overall response rate was 12.5%and the disease control rate was 54.2%.The median progression-free survival(PFS)was 4 months.Treatment was tolerated with serious toxicity.Conclusion:Oral S1 metronomic chemotherapy combing with docetaxel can be used as a treatment regimen for patients with advanced NSCLC selectivity,but the optimal dosage and combination should be further explored.